Amylyx investor share sale not due to disagreement, says Mizuho

Mizuho analyst Graig Suvannavejh tells investors in a research note that Morningside Ventures, the top shareholder of Amylyx, sold 2M shares last week, while also donating 2M shares, which is likely to have been a key contributor to the selling pressure, where last Friday, Amylyx shares traded intra-day below the $20 level. The firm believes that the sale by Morningside is not related to a fundamental disagreement with future prospects of Amylys, but is instead a decision to monetize its position in the company. Mizuho recommends buying the current weakness.